SCHEMBL1129291

SCHEMBL1129291

COc1cc(Br)c(C)cc1Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C19 P33261 2/20 0.45
LTA4H P09960 1/20 0.42
NTRK1 P04629 2/20 0.42
NTRK2 Q16620 2/20 0.42
IGF1R P08069 1/20 0.42
FGFR1 P11362 1/20 0.42
MAPT P10636 3/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NTRK3 Q16288 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CHRNA7 P36544 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17466060 0.84 NTRK1 (0.42) ALDH1A1HTTCYP1A2CYP2C19LTA4H
SCHEMBL20521390 0.83 TTR (0.47) TTRL3MBTL1ALDH1A1MAPK1HTT
SCHEMBL1129166 0.81 TTR (0.46) TTRL3MBTL1ALDH1A1MAPK1HTT
SCHEMBL1505362 0.81 MAPT (0.52) L3MBTL1CYP1A2CYP2C19MAPTLCK
SCHEMBL17466061 0.79 CYP1A2 (0.49) L3MBTL1ALDH1A1HTTCYP1A2CYP2C19
SCHEMBL29025658 0.79 KMT2A (0.50) TTRL3MBTL1ALDH1A1MAPK1HTT
SCHEMBL9102126 0.77 DHODH (0.44) CYP1A2CYP2C19LTA4HBRD4
SCHEMBL4596187 0.76 MEN1 (0.54) L3MBTL1ALDH1A1MAPK1CYP1A2CYP2C19
SCHEMBL20562352 0.76 MEN1 (0.54) L3MBTL1ALDH1A1MAPK1CYP1A2CYP2C19
Anisole SCHEMBL8144116 0.75 CA4 (0.64) TTRCYP1A2LTA4HMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
EP-2283020-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009143051-A1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-26 WO disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 TTR 575/4885L3MBTL1 4613/4885ALDH1A1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.